<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144048</url>
  </required_header>
  <id_info>
    <org_study_id>261787/2021</org_study_id>
    <nct_id>NCT05144048</nct_id>
  </id_info>
  <brief_title>Outpatient Induction of Labor With Oral Misoprostol</brief_title>
  <official_title>Outpatient Induction of Labor With Oral Misoprostol: A Multicenter Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of labor is an increasingly used intervention in obstetrics due to expanding&#xD;
      indications, which more often includes relatively healthy women with uncomplicated&#xD;
      pregnancies. While induction of labor traditionally is offered in an inpatient setting, a&#xD;
      shift towards an outpatient setting is increasing despite insufficient evidence regarding&#xD;
      safety and effectiveness. Oral misoprostol is easy for the pregnant women to administer and&#xD;
      the risk of uterine hyperstimulation with fetal heart rate changes is found to be low. Strong&#xD;
      evidence concludes that oral misoprostol is preferable as an induction agent and is&#xD;
      recommended by the World Health Organization (WHO).&#xD;
&#xD;
      The investigators will perform a multicenter randomized-controlled trial comparing labor&#xD;
      induction in an outpatient versus inpatient setting, aiming to increase knowledge on&#xD;
      outpatient induction of labor with oral misoprostol. The study is based on experiences and&#xD;
      findings from a recently performed pilot trial and targets a large group of relatively&#xD;
      healthy pregnant women where induction of labor is decided.&#xD;
&#xD;
      The investigators hypothesize that women induced in an outpatient setting will be more&#xD;
      satisfied than women induced in an inpatient setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After induction of labor is decided the women will be recruited according to inclusion and&#xD;
      exclusion criteria's.&#xD;
&#xD;
      The inpatient induction group will receive the following treatment:&#xD;
&#xD;
      Oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6&#xD;
      hours until start of contractions, the next 48 hours while admitted to the maternity ward.&#xD;
      The participating women will be transferred to the labor ward by start of contractions or&#xD;
      need for closer fetal surveillance and/or analgesia.&#xD;
&#xD;
      The outpatient induction group will receive the following treatment:&#xD;
&#xD;
      These participating women receive the first oral misoprostol 25ug at the maternity unit.&#xD;
      After two hours if the cardiotocograph is normal and there are no signs of contractions,&#xD;
      these women go home. At home, the women will continue to take 25ug misoprostol every two&#xD;
      hours until 22 pm or until the contractions begin. Maximum time spent at home is 48 hours and&#xD;
      maximum number of tablets is 12 during this period (6 tablets each day). The women will also&#xD;
      receive oral and written information regarding when to return to the maternity ward.&#xD;
      Information sheets for the midwives and included women will be adapted from those used in the&#xD;
      pilot study.&#xD;
&#xD;
      If the contractions are still absent after 48 hours or a maximum of 12 tablets (6 per day),&#xD;
      all women (both inpatient and outpatient) are admitted to the maternity ward for further&#xD;
      induction of labor. All women will receive equal standard of care including fetal&#xD;
      surveillance after admittance to the hospital. Further follow up is in accordance with&#xD;
      standard procedure of the maternity ward. Questions about fidelity to the proposed protocol&#xD;
      across sites will be asked in the patient questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All eligible women will be recruited form a midwife and/or doctor. After the inclusion they will be randomized to either inpatient or outpatient setting.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The women will be randomized using a secure survey tool (Nettskjema) to an inpatient or outpatient setting..</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal childbirth experience and maternal experience with induction of labor</measure>
    <time_frame>up to 12 days after delivery</time_frame>
    <description>The women will answer electronic questionaires at inclusion and postpartum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Labor outcomes</measure>
    <time_frame>From 1 hour to average of 48 hours</time_frame>
    <description>Hours from start induction and start active labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per delivery</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>We will calculate the differences of costs and effects of one or more alternatives, and present the differences in the form of a ratio (ICER), i.e. the cost per unit of health outcome or effect. We will calculate cost-effectiveness (δ costs / δ effects) to evaluate whether outpatient induction shows to be dominant strategy regarding patient satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>Induction of labour with oral misoprostol, inpatient setting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These women receive all treatment in the maternity unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction of labour with oral misoprostol, outpatient setting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These women are observed 2 hours after they receive one dose of oral misoprostol before they leave the maternity unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inpatient setting</intervention_name>
    <description>These women stay at the maternity unit</description>
    <arm_group_label>Induction of labour with oral misoprostol, inpatient setting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Outpatient setting</intervention_name>
    <description>These women leave the maternity unit</description>
    <arm_group_label>Induction of labour with oral misoprostol, outpatient setting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 37 gestational weeks, vertex presentation, single pregnancy&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Understand and read Norwegian&#xD;
&#xD;
          -  Distance to hospital less than 1 hour&#xD;
&#xD;
          -  Normal ultrasound including:&#xD;
&#xD;
               -  fetal movements&#xD;
&#xD;
               -  amniotic fluid (deepest single vertical pocket) &gt; 2 cm&#xD;
&#xD;
               -  estimated fetal weight ≥ -15% (≥ 10 percentile)&#xD;
&#xD;
          -  Normal antenatal cardiotocography&#xD;
&#xD;
          -  Women with stable hypertension and uncomplicated preeclampsia without indication for&#xD;
             inpatient treatment can be included after individual assessment.&#xD;
&#xD;
          -  Access to partner or contact person at home for transportation to hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Premature rupture of membranes&#xD;
&#xD;
          -  Uterine scar&#xD;
&#xD;
          -  BMI ≥ 40&#xD;
&#xD;
          -  Abnormal fetal Doppler (if examined); umbilical artery pulsatility index ≥ 95&#xD;
             percentile and/or cerebroplacental ratio &lt;1&#xD;
&#xD;
          -  Fetal anomaly or chromosomic / genetic disorder&#xD;
&#xD;
          -  Grand multipara (P≥4)&#xD;
&#xD;
          -  Cognitive barriers&#xD;
&#xD;
          -  Pregnancy complications such as preeclampsia requiring in-hospital treatment, insulin&#xD;
             dependent diabetes or other conditions associated with risk of fetal hypoxia during&#xD;
             labor&#xD;
&#xD;
          -  Signs of infection or serious health problems&#xD;
&#xD;
          -  Favorable cervix and / or previous obstetric history providing contraindications for&#xD;
             induction with misoprostol&#xD;
&#xD;
          -  Combined risk factors, individually evaluated by the attending obstetrician&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne Rossen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sorlandet HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janne Rossen, MD, PhD</last_name>
    <phone>38076266</phone>
    <phone_ext>+47</phone_ext>
    <email>janne.rossen@sshf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fride E Austad, MD</last_name>
    <email>fride.efjestad.austad@sshf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sorlandet Hospital Trust</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>WHO recommendations: Induction of labour at or beyond term. Geneva: World Health Organization; 2018.</citation>
    <PMID>30629393</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfirevic Z, Gyte GM, Nogueira Pileggi V, Plachcinski R, Osoti AO, Finucane EM. Home versus inpatient induction of labour for improving birth outcomes. Cochrane Database Syst Rev. 2020 Aug 27;8:CD007372. doi: 10.1002/14651858.CD007372.pub4.</citation>
    <PMID>32852803</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014 Jun 13;(6):CD001338. doi: 10.1002/14651858.CD001338.pub3. Review.</citation>
    <PMID>24924489</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonagh M, Skelly AC, Tilden E, Brodt ED, Dana T, Hart E, Kantner SN, Fu R, Hermesch AC. Outpatient Cervical Ripening: A Systematic Review and Meta-analysis. Obstet Gynecol. 2021 Jun 1;137(6):1091-1101. doi: 10.1097/AOG.0000000000004382.</citation>
    <PMID>33752219</PMID>
  </results_reference>
  <results_reference>
    <citation>Helmig RB, Hvidman LE. An audit of oral administration of Angusta® (misoprostol) 25 µg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. Acta Obstet Gynecol Scand. 2020 Oct;99(10):1396-1402. doi: 10.1111/aogs.13876. Epub 2020 May 19.</citation>
    <PMID>32311758</PMID>
  </results_reference>
  <results_reference>
    <citation>Ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, Holswilder M, Oudijk MA, van Baaren GJ, Pernet PJ, Bax C, van Unnik GA, Martens G, Porath M, van Vliet H, Rijnders RJ, Feitsma AH, Roumen FJ, van Loon AJ, Versendaal H, Weinans MJ, Woiski M, van Beek E, Hermsen B, Mol BW, Bloemenkamp KW. Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. Lancet. 2016 Apr 16;387(10028):1619-28. doi: 10.1016/S0140-6736(16)00084-2. Epub 2016 Feb 3.</citation>
    <PMID>26850983</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>induction</keyword>
  <keyword>outpatient</keyword>
  <keyword>misoprostol</keyword>
  <keyword>childbirth experience</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

